Adam Maghrabi, MD
Endocrinology, Diabetes & Metabolism · Blue Springs, MONPI 1447488671
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $99,478 of the $120,312 with a category attached, or 82.7%. Lilly USA, LLC accounts for 68.0% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $43,747 and has fallen 82.0% since, to $7,894 in 2025. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 388 payments — averaging $310.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$82K
- Boehringer Ingelheim$21K
- Dexcom, Inc.$14K
- Abbott$2K
- Novo Nordisk$278
- AstraZeneca$249
- plus $2K from 30 others
What the payments were for
- Consulting fees$2,9252%
- Speaking & faculty fees$99,47883%
- Travel & lodging$11,76810%
- Food & beverage$6,1415%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 185 | $81,770 |
| Boehringer Ingelheim | 46 | $20,685 |
| Dexcom, Inc. | 27 | $13,645 |
| Abbott | 7 | $2,087 |
| Novo Nordisk | 18 | $278 |
| AstraZeneca(2 entities) | 16 | $249 |
| Sanofi-aventis U.S. LLC | 13 | $242 |
| Merck | 10 | $161 |
| Mannkind Corporation | 7 | $121 |
| Insulet Corporation | 5 | $99 |
| Tandem Diabetes Care, Inc. | 7 | $93 |
| Cequr Corporation | 2 | $91 |
| Sanofi | 1 | $72 |
| Medtronic(2 entities) | 5 | $68 |
| Nevro Corp. | 3 | $63 |
| Pfizer | 4 | $61 |
| Amgen(2 entities) | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 4 | $60 |
| Johnson & Johnson(2 entities) | 3 | $55 |
| Amarin Pharma, Inc. | 3 | $48 |
| AbbVie | 3 | $41 |
| Corcept Therapeutics | 2 | $30 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| Bayer | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $19 |
| Senseonics, Incorporated | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Lifescan, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Zimmer Biomet | 1 | $13 |
| Radius Health, Inc. | 1 | $13 |
| Zealand Pharma US, Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$48,573
- JARDIANCE$40,061
- DEXCOM CGM$9,647
- DEXCOM G6 CGM SYSTEM$3,602
- FreeStyle Libre Pro$2,063
How this compares
$120,312 in reported general payments places this provider in the 90th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 280 | $373,437 |
| TrulicityDulaglutide | 185 | $308,875 |
| OzempicSemaglutide | 179 | $284,611 |
| Tresiba Flextouch U-100Insulin Degludec | 155 | $153,260 |
| Tresiba Flextouch U-200Insulin Degludec | 66 | $135,643 |
| MounjaroTirzepatide | 88 | $117,037 |
| FarxigaDapagliflozin Propanediol | 109 | $108,834 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $79,754 |
| RybelsusSemaglutide | 42 | $66,129 |
| JanuviaSitagliptin Phosphate | 46 | $54,923 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $50,801 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $46,553 |
| Novolog FlexpenInsulin Aspart | 109 | $44,935 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 50 | $38,719 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 182 | $33,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $81,770 | $431,440298 claims |
| Boehringer IngelheimJardiance | $20,685 | $373,437280 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $278 | $364,022252 claims |
| AstraZenecaFarxiga | $249 | $108,834109 claims |
| MerckJanuvia | $161 | $54,92346 claims |
| Sanofi-aventis U.S. LLCLantus | $242 | $8,06228 claims |
| AbbVieSynthroid | $41 | $6,08054 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Blue Springs
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
- Christopher CaseJefferson City$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.